NCT05492682View on ClinicalTrials.gov

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

December 31, 2026

Conditions
Melanoma (Skin)Triple-Negative Breast CancerNon-Small Cell Lung CancerSynovial SarcomaMyxoid LiposarcomaColorectal CancerOsteosarcomaSarcoma
Interventions
DRUG

PeptiCRAd-1

All patients will receive PeptiCRAd-1.

DRUG

Cyclophosphamide

All patients will be pre-treated with one single dose of Cyclophosphamide.

DRUG

Pembrolizumab

All patients will receive 6 doses of Pembrolizumab within the study.

Trial Locations (3)

Unknown

Krankenhaus Nordwest, Frankfurt

National Center for Tumor Diseases, Heidelberg

Universitätsklinikum Tübingen, Tübingen

All Listed Sponsors
lead

Valo Therapeutics Oy

INDUSTRY